Mutated and Bacteriophage T4 Nanoparticle Arrayed F1-V Immunogens from Yersinia pestis as Next Generation Plague Vaccines

PLoS Pathogens

Volumn 9, Issue 7, 2013, Pages

  Tao, Pan ^a   Mahalingam, Marthandan ^a   Kirtley, Michelle L ^b   van Lier, Christina J ^b   Sha, Jian ^b,c   Yeager, Linsey A ^b,c   Chopra, Ashok K ^b,c   Rao, Venigalla B ^a  

^a CATHOLIC UNIVERSITY OF AMERICA   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSULAR PROTEIN F1; EPITOPE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 10; LOW CALCIUM RESPONSE V ANTIGEN; NANOPARTICLE; PLAGUE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE T4; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PLAGUE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RAT; SOLUBILITY; STRUCTURAL BIOINFORMATICS; YERSINIA PESTIS;

EID: 84884751020     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003495     Document Type: Article

References (65)

1. Perry RD, Fetherston JD, (1997) Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10: 35-66.
2. Kool JL, (2005) Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis 40: 1166-1172.
3. Rosenzweig JA, Jejelowo O, Sha J, Erova TE, Brackman SM, et al. (2011) Progress on plague vaccine development. Appl Microbiol Biotechnol 91: 265-286.
4. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, et al. (2000) Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283: 2281-2290.
5. Zilinskas RA, (2006) The anti-plague system and the Soviet biological warfare program. Crit Rev Microbiol 32: 47-64.
6. Smiley ST, (2008) Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 7: 209-221.
7. Sha J, Kirtley ML, van Lier CJ, Wang S, Erova TE, et al. (2013) Deletion of Braun lipoprotein encoding gene and altering the function of lipopolysaccharide attenuate plague bacterium. Infect Immun 81 (3) (): 815-28.
8. Feodorova VA, Corbel MJ, (2009) Prospects for new plague vaccines. Expert Rev Vaccines 8: 1721-1738.
9. Williamson ED, Oyston PC, (2012) The natural history and incidence of Yersinia pestis and prospects for vaccination. J Med Microbiol 61: 911-918.
10. Zavialov AV, Berglund J, Pudney AF, Fooks LJ, Ibrahim TM, et al. (2003) Structure and biogenesis of the capsular F1 antigen from Yersinia pestis: preserved folding energy drives fiber formation. Cell 113: 587-596.
11. Stenseth NC, Atshabar BB, Begon M, Belmain SR, Bertherat E, et al. (2008) Plague: past, present, and future. PLoS Med 5: e3.
12. Derewenda U, Mateja A, Devedjiev Y, Routzahn KM, Evdokimov AG, et al. (2004) The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague. Structure 12: 301-306.
13. Brubaker RR, (2003) Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun 71: 3673-3681.
14. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, et al. (1995) A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12: 223-230.
15. Anderson GW Jr, Heath DG, Bolt CR, Welkos SL, Friedlander AM, (1998) Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58: 793-799.
16. Heath DG, Anderson GW Jr, Mauro JM, Welkos SL, Andrews GP, et al. (1998) Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16: 1131-1137.
17. Williamson ED, (2009) Plague. Vaccine 27 Suppl 4: D56-60.
18. Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, et al. (2005) Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73: 3598-3608.
19. Mizel SB, Graff AH, Sriranganathan N, Ervin S, Lees CJ, et al. (2009) Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol 16: 21-28.
20. Goodin JL, Nellis DF, Powell BS, Vyas VV, Enama JT, et al. (2007) Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Expr Purif 53: 63-79.
21. Goodin JL, Powell BS, Enama JT, Raab RW, McKown RL, et al. (2011) Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague. Protein Expr Purif 76: 136-144.
22. Powell BS, Andrews GP, Enama JT, Jendrek S, Bolt C, et al. (2005) Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21: 1490-1510.
23. Parent MA, Berggren KN, Kummer LW, Wilhelm LB, Szaba FM, et al. (2005) Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 73: 7304-7310.
24. Friedlander AM, Welkos SL, Worsham PL, Andrews GP, Heath DG, et al. (1995) Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis 21 Suppl 2: S178-181.
25. Worsham PL, Stein MP, Welkos SL, (1995) Construction of defined F1 negative mutants of virulent Yersinia pestis. Contrib Microbiol Immunol 13: 325-328.
26. Roggenkamp A, Geiger AM, Leitritz L, Kessler A, Heesemann J, (1997) Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 65: 446-451.
27. Erova TE, Rosenzweig JA, Sha J, Suarez G, Sierra JC, et al. (2013) Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new generation recombinant plague vaccine. Clin Vaccine Immunol 20: 227-238.
28. DeBord KL, Anderson DM, Marketon MM, Overheim KA, DePaolo RW, et al. (2006) Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. Infect Immun 74: 4910-4914.
29. Li Q, Shivachandra SB, Leppla SH, Rao VB, (2006) Bacteriophage T4 capsid: a unique platform for efficient surface assembly of macromolecular complexes. J Mol Biol 363: 577-588.
30. Li Q, Shivachandra SB, Zhang Z, Rao VB, (2007) Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid. J Mol Biol 370: 1006-1019.
31. Shivachandra SB, Li Q, Peachman KK, Matyas GR, Leppla SH, et al. (2007) Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 25: 1225-1235.
32. Sathaliyawala T, Rao M, Maclean DM, Birx DL, Alving CR, et al. (2006) Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J Virol 80: 7688-7698.
33. Black LW, Rao VB, (2012) Structure, assembly, and DNA packaging of the bacteriophage T4 head. Adv Virus Res 82: 119-153.
34. Qin L, Fokine A, O'Donnell E, Rao VB, Rossmann MG, (2009) Structure of the small outer capsid protein, Soc: a clamp for stabilizing capsids of T4-like phages. J Mol Biol 395: 728-741.
35. Fokine A, Islam MZ, Zhang Z, Bowman VD, Rao VB, et al. (2011) Structure of the three N-terminal immunoglobulin domains of the highly immunogenic outer capsid protein from a T4-like bacteriophage. J Virol 85: 8141-8148.
36. Sathaliyawala T, Islam MZ, Li Q, Fokine A, Rossmann MG, et al. (2010) Functional analysis of the highly antigenic outer capsid protein, Hoc, a virus decoration protein from T4-like bacteriophages. Mol Microbiol 77: 444-455.
37. Ishii T, Yanagida M, (1977) The two dispensable structural proteins (soc and hoc) of the T4 phage capsid; their purification and properties, isolation and characterization of the defective mutants, and their binding with the defective heads in vitro. J Mol Biol 109: 487-514.
38. Andrews GP, Heath DG, Anderson GW Jr, Welkos SL, Friedlander AM, (1996) Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64: 2180-2187.
39. Miller J, Williamson ED, Lakey JH, Pearce MJ, Jones SM, et al. (1998) Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol Med Microbiol 21: 213-221.
40. Musson JA, Morton M, Walker N, Harper HM, McNeill HV, et al. (2006) Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes. J Biol Chem 281: 26129-26135.
41. Overheim KA, Depaolo RW, Debord KL, Morrin EM, Anderson DM, et al. (2005) LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 73: 5152-5159.
42. Matson JS, Durick KA, Bradley DS, Nilles ML, (2005) Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol 5: 38.
43. Davis AJ, Mecsas J, (2007) Mutations in the Yersinia pseudotuberculosis type III secretion system needle protein, YscF, that specifically abrogate effector translocation into host cells. J Bacteriol 189: 83-97.
44. Quenee LE, Schneewind O, (2009) Plague vaccines and the molecular basis of immunity against Yersinia pestis. Hum Vaccin 5: 817-823.
45. Smiley ST, (2008) Immune defense against pneumonic plague. Immunol Rev 225: 256-271.
46. Do Y, Park CG, Kang YS, Park SH, Lynch RM, et al. (2008) Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur J Immunol 38: 20-29.
47. Agar SL, Sha J, Foltz SM, Erova TE, Walberg KG, et al. (2009) Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92. Microbes Infect 11: 205-214.
48. Chalton DA, Musson JA, Flick-Smith H, Walker N, McGregor A, et al. (2006) Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation. Infect Immun 74: 6624-6631.
49. Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, et al. (2002) Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 196: 1017-1024.
50. Sodhi A, Sharma RK, Batra HV, (2005) Yersinia rLcrV and rYopB inhibits the activation of murine peritoneal macrophages in vitro. Immunol Lett 99: 146-152.
51. Lin JS, Park S, Adamovicz JJ, Hill J, Bliska JB, et al. (2010) TNFalpha and IFNgamma contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine 29: 357-362.
52. Kopp E, Medzhitov R, (2002) A plague on host defense. J Exp Med 196: 1009-1012.
53. Wang S, Goguen JD, Li F, Lu S, (2011) Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine 29: 6802-6809.
54. Philipovskiy AV, Smiley ST, (2007) Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun 75: 878-885.
55. Amemiya K, Meyers JL, Rogers TE, Fast RL, Bassett AD, et al. (2009) CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine 27: 2220-2229.
56. Hickey AJ, Lin JS, Kummer LW, Szaba FM, Duso DK, et al. (2013) Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection. Infect Immun 81 (6) (): 2123-32.
57. Peachman KK, Li Q, Matyas GR, Shivachandra SB, Lovchik J, et al. (2012) Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores. Clin Vaccine Immunol 19: 11-16.
58. Rao M, Peachman KK, Li Q, Matyas GR, Shivachandra SB, et al. (2011) Highly effective generic adjuvant systems for orphan or poverty-related vaccines. Vaccine 29: 873-877.
59. Bruttin A, Brussow H, (2005) Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49: 2874-2878.
60. Tao P, Mahalingam M, Marasa BS, Zhang Z, Chopra AK, et al. (2013) In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine. Proc Natl Acad Sci U S A 110: 5846-5851.
61. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR, (1989) Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77: 61-68.
62. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612.
63. Hu X, Zhou W, Udaka K, Mamitsuka H, Zhu S, (2010) MetaMHC: a meta approach to predict peptides binding to MHC molecules. Nucleic Acids Res 38: W474-479.
64. Brito LA, Singh M, (2011) Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci 100: 34-37.
65. Agar SL, Sha J, Foltz SM, Erova TE, Walberg KG, et al. (2008) Characterization of a mouse model of plague after aerosolization of Yersinia pestis CO92. Microbiology 154: 1939-1948.